Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Grand View Research | PRODUCT CODE: 2067601

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2067601

Antibiotic Resistance Market Size, Share & Trends Analysis Report By Disease, By Pathogen, By Drug Class, By Mechanism Of Action, By Distribution Channel, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Antibiotic Resistance Market Summary

The global antibiotic resistance market size was estimated at USD 9.65 billion in 2025 and is projected to grow from USD 10.15 billion in 2026 to USD 14.26 billion by 2033, at a CAGR of 4.98% from 2026 to 2033. The North America antibiotic resistance market held the largest global share of 36.47% in 2025.

Increasing resistance among pathogens such as Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Acinetobacter baumannii is creating significant pressure on healthcare systems worldwide. The growing incidence of hospital-acquired, bloodstream, urinary tract, and respiratory infections is accelerating the need for advanced antibacterial therapies and rapid diagnostic technologies. Additionally, rising mortality rates from resistant infections and the expanding clinical burden in intensive care settings are driving demand for novel antimicrobial agents.

The growth of the antibiotic resistance industry is also driven by increasing investments in antibiotic innovation, non-traditional antibacterial therapies, and precision diagnostic platforms. Pharmaceutical companies, biotechnology firms, and academic institutions are increasingly focusing on the development of next-generation antibiotics, bacteriophage therapies, microbiome-based therapeutics, monoclonal antibodies, and AI-assisted drug discovery platforms to combat resistant pathogens. For instance, in October 2025, the World Health Organization highlighted that the global antibacterial pipeline remains insufficient despite ongoing innovation efforts, emphasizing the urgent requirement for new chemical classes and improved oral treatment options. Furthermore, the growing integration of artificial intelligence into antimicrobial drug discovery is accelerating compound screening and the development of pathogen-targeted therapies. Rising funding support for small and mid-sized biotechnology companies engaged in antibacterial R&D is further contributing to technological advancements and strengthening long-term market growth opportunities.

Strategic collaborations, international funding initiatives, and public-private partnerships are increasingly shaping the competitive landscape of the antibiotic resistance market. Governments, regulatory agencies, and healthcare organizations are strengthening global coordination to improve antibiotic accessibility, surveillance systems, and antimicrobial research infrastructure. The growing focus on One Health initiatives integrating human, animal, and environmental health is also contributing to broader antimicrobial resistance management strategies. Additionally, increased investments in diagnostics, surveillance programs, and antibacterial development targeting WHO priority pathogens are supporting market growth. Healthcare authorities across North America, Europe, and Asia Pacific are expanding funding for antimicrobial innovation programs to address the rising socioeconomic burden of resistant infections. These initiatives are expected to accelerate the commercialization of novel therapies and enhance long-term market sustainability in the global antibiotic resistance treatment landscape.

Global Antibiotic Resistance Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antibiotic resistance market report based on disease, pathogen, mechanism of action, drug class, distribution channel, and region:

  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • cUTI (Complicated Urinary Tract Infections)
  • CDI (Clostridioides difficile Infection)
  • ABSSSI (Acute bacterial skin and skin structure infections)
  • HABP (Hospital-acquired bacterial pneumonia)
  • CABP
  • cIAI
  • BSI
  • Pathogen Outlook (Revenue, USD Million, 2021 - 2033)
  • E. coli
  • klebsiella pneumoniae
  • P. aeruginosa
  • S. aureus
  • A. baumannii
  • Strep. pneumoniae
  • H. influenzae
  • CDI
  • Enterococcus faecium
  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Combination therapies
  • Cephalosporins
  • Others
  • Mechanism of Action Outlook (Revenue, USD Million, 2021 - 2033)
  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-2-68038-663-9

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Pathogen
    • 1.2.3. Drug Class
    • 1.2.4. Mechanism of Action
    • 1.2.5. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Antibiotic Resistance Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Antibiotic Resistance Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2025 & 2033
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 4.4. cUTI (Complicated Urinary Tract Infections)
    • 4.4.1. cUTI (Complicated Urinary Tract Infections) Market, 2021 - 2033 (USD Million)
  • 4.5. CDI (Clostridioides difficile Infection)
    • 4.5.1. CDI (Clostridioides difficile Infection) Market, 2021 - 2033 (USD Million)
  • 4.6. ABSSSI (Acute bacterial skin and skin structure infections)
    • 4.6.1. ABSSSI (Acute bacterial skin and skin structure infections) Market, 2021 - 2033 (USD Million)
  • 4.7. HABP (Hospital-acquired bacterial pneumonia)
    • 4.7.1. HABP (Hospital-acquired bacterial pneumonia) Market, 2021 - 2033 (USD Million)
  • 4.8. CABP (Community-acquired pneumonia)
    • 4.8.1. CABP (Community-acquired pneumonia) Market, 2021 - 2033 (USD Million)
  • 4.9. cIAI (Complicated intra-abdominal infection)
    • 4.9.1. cIAI (Complicated intra-abdominal infection) Market, 2021 - 2033 (USD Million)
  • 4.10. BSI (Bloodstream infection)
    • 4.10.1. BSI (Bloodstream infection) Market, 2021 - 2033 (USD Million)

Chapter 5. Antibiotic Resistance Market: Pathogen Business Analysis

  • 5.1. Pathogen Market Share, 2025 & 2033
  • 5.2. Pathogen Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Pathogen, 2021 to 2033 (USD Million)
  • 5.4. E. coli
    • 5.4.1. E. coli Market, 2021 - 2033 (USD Million)
  • 5.5. K. pneumoniae
    • 5.5.1. K. pneumoniae Market, 2021 - 2033 (USD Million)
  • 5.6. P. aeruginosa
    • 5.6.1. P. aeruginosa Market, 2021 - 2033 (USD Million)
  • 5.7. S. aureus
    • 5.7.1. S. aureus Market, 2021 - 2033 (USD Million)
  • 5.8. A. baumannii
    • 5.8.1. A. baumannii Market, 2021 - 2033 (USD Million)
  • 5.9. S. pneumoniae
    • 5.9.1. S. pneumoniae Market, 2021 - 2033 (USD Million)
  • 5.10. H. influenzae
    • 5.10.1. H. influenzae Market, 2021 - 2033 (USD Million)
  • 5.11. CDI
    • 5.11.1. CDI Market, 2021 - 2033 (USD Million)
  • 5.12. E. faecium
    • 5.12.1. E. faecium Market, 2021 - 2033 (USD Million)

Chapter 6. Antibiotic Resistance Market: Drug Class Business Analysis

  • 6.1. Drug Class Market Share, 2025 & 2033
  • 6.2. Drug Class Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 6.4. Oxazolidinones
    • 6.4.1. Oxazolidinones Market, 2021 - 2033 (USD Million)
  • 6.5. Lipoglycopeptides
    • 6.5.1. Lipoglycopeptides Market, 2021 - 2033 (USD Million)
  • 6.6. Tetracyclines
    • 6.6.1. Tetracyclines Market, 2021 - 2033 (USD Million)
  • 6.7. Combination therapies
    • 6.7.1. Combination Therapies Market, 2021 - 2033 (USD Million)
  • 6.8. Cephalosporins
    • 6.8.1. Cephalosporins Market, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Antibiotic Resistance Market: Mechanism of Action Business Analysis

  • 7.1. Mechanism of Action Market Share, 2025 & 2033
  • 7.2. Mechanism of Action Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Mechanism of Action, 2021 to 2033 (USD Million)
  • 7.4. Protein Synthesis Inhibitors
    • 7.4.1. Protein Synthesis Inhibitors Market, 2021 - 2033 (USD Million)
  • 7.5. Cell Wall Synthesis Inhibitors
    • 7.5.1. Cell Wall Synthesis Inhibitors Market, 2021 - 2033 (USD Million)
  • 7.6. RNA Synthesis Inhibitors
    • 7.6.1. RNA Synthesis Inhibitors Market, 2021 - 2033 (USD Million)
  • 7.7. DNA Synthesis Inhibitors
    • 7.7.1. DNA Synthesis Inhibitors Market, 2021 - 2033 (USD Million)
  • 7.8. Others
    • 7.8.1. Others Synthesis Inhibitors Market, 2021 - 2033 (USD Million)

Chapter 8. Antibiotic Resistance Market: Distribution Channel Business Analysis

  • 8.1. Distribution Channel Market Share, 2025 & 2033
  • 8.2. Distribution Channel Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 8.4. Hospital Pharmacies
    • 8.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 8.5. Retail Pharmacies
    • 8.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 8.6. Online Pharmacies
    • 8.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 9. Antibiotic Resistance Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2025 & 2033
  • 9.2. Regional Market Dashboard
  • 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 9.4. North America
    • 9.4.1. North America Antibiotic Resistance Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.4.2. U.S.
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Target Disease Prevalence
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. Reimbursement Framework
      • 9.4.2.5. U.S. Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Target Disease Prevalence
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Reimbursement Framework
      • 9.4.3.5. Canada Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Target Disease Prevalence
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. Reimbursement Framework
      • 9.4.4.5. Mexico Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Europe
    • 9.5.1. Europe Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Target Disease Prevalence
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Reimbursement Framework
      • 9.5.2.5. UK Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Target Disease Prevalence
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. Reimbursement Framework
      • 9.5.3.5. Germany Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.4. France
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Target Disease Prevalence
      • 9.5.4.3. Regulatory Framework
      • 9.5.4.4. Reimbursement Framework
      • 9.5.4.5. France Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.5. Italy
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Target Disease Prevalence
      • 9.5.5.3. Regulatory Framework
      • 9.5.5.4. Reimbursement Framework
      • 9.5.5.5. Italy Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Target Disease Prevalence
      • 9.5.6.3. Regulatory Framework
      • 9.5.6.4. Reimbursement Framework
      • 9.5.6.5. Spain Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.7. Denmark
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Target Disease Prevalence
      • 9.5.7.3. Regulatory Framework
      • 9.5.7.4. Reimbursement Framework
      • 9.5.7.5. Denmark Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.8. Sweden
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Target Disease Prevalence
      • 9.5.8.3. Regulatory Framework
      • 9.5.8.4. Reimbursement Framework
      • 9.5.8.5. Sweden Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.9. Norway
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Target Disease Prevalence
      • 9.5.9.3. Regulatory Framework
      • 9.5.9.4. Reimbursement Framework
      • 9.5.9.5. Norway Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.2. Japan
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Target Disease Prevalence
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Reimbursement Framework
      • 9.6.2.5. Japan Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.3. China
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Target Disease Prevalence
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Reimbursement Framework
      • 9.6.3.5. China Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.4. India
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Target Disease Prevalence
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. Reimbursement Framework
      • 9.6.4.5. India Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.5. Australia
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Target Disease Prevalence
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. Reimbursement Framework
      • 9.6.5.5. Australia Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.6. South Korea
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Target Disease Prevalence
      • 9.6.6.3. Regulatory Framework
      • 9.6.6.4. Reimbursement Framework
      • 9.6.6.5. South Korea Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Target Disease Prevalence
      • 9.6.7.3. Regulatory Framework
      • 9.6.7.4. Reimbursement Framework
      • 9.6.7.5. Thailand Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7. Latin America
    • 9.7.1. Latin America Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Target Disease Prevalence
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. Reimbursement Framework
      • 9.7.2.5. Brazil Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Target Disease Prevalence
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. Reimbursement Framework
      • 9.7.3.5. Argentina Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8. Middle East and Africa
    • 9.8.1. Middle East and Africa Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Target Disease Prevalence
      • 9.8.2.3. Regulatory Framework
      • 9.8.2.4. Reimbursement Framework
      • 9.8.2.5. South Africa Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Target Disease Prevalence
      • 9.8.3.3. Regulatory Framework
      • 9.8.3.4. Reimbursement Framework
      • 9.8.3.5. Saudi Arabia Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Target Disease Prevalence
      • 9.8.4.3. Regulatory Framework
      • 9.8.4.4. Reimbursement Framework
      • 9.8.4.5. UAE Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Target Disease Prevalence
      • 9.8.5.3. Regulatory Framework
      • 9.8.5.4. Reimbursement Framework
      • 9.8.5.5. Kuwait Antibiotic Resistance Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Melinta Therapeutics
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Product Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. Basilea Pharmaceutica Ltd.
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Product Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. Tetraphase Pharmaceuticals
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Product Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. Theravance Biopharma
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Product Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. WOCKHARDT
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Product Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Paratek Pharmaceuticals, Inc.
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Product Benchmarking
      • 10.5.6.4. Strategic Initiatives
    • 10.5.7. Seres Therapeutics
      • 10.5.7.1. Overview
      • 10.5.7.2. Financial Performance
      • 10.5.7.3. Product Benchmarking
      • 10.5.7.4. Strategic Initiatives
    • 10.5.8. ACHAOGEN, INC.
      • 10.5.8.1. Overview
      • 10.5.8.2. Financial Performance
      • 10.5.8.3. Product Benchmarking
      • 10.5.8.4. Strategic Initiatives
    • 10.5.9. Entasis Therapeutics
      • 10.5.9.1. Overview
      • 10.5.9.2. Financial Performance
      • 10.5.9.3. Product Benchmarking
      • 10.5.9.4. Strategic Initiatives
    • 10.5.10. AbbVie
      • 10.5.10.1. Overview
      • 10.5.10.2. Financial Performance
      • 10.5.10.3. Product Benchmarking
      • 10.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-2-68038-663-9

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global antibiotic resistance market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 5. Global antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 6. Global antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 7. Global antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 8. Global antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9. North America antibiotic resistance market, by country, 2021 - 2033 (USD Million)
  • Table 10. North America antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 11. North America antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 12. North America antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 13. North America antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 14. North America antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15. U.S. antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 16. U.S. antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 17. U.S. antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 18. U.S. antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 19. U.S. antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20. Canada antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 21. Canada antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 22. Canada antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 23. Canada antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 24. Canada antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25. Mexico antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 26. Mexico antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 27. Mexico antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 28. Mexico antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 29. Mexico antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30. Europe antibiotic resistance market, by country, 2021 - 2033 (USD Million)
  • Table 31. Europe antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 32. Europe antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 33. Europe antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 34. Europe antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 35. Europe antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36. UK antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 37. UK antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 38. UK antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 39. UK antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 40. UK antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41. Germany antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 42. Germany antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 43. Germany antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 44. Germany antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 45. Germany antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46. France antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 47. France antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 48. France antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 49. France antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 50. France antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 51. Italy antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 52. Italy antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 53. Italy antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 54. Italy antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 55. Italy antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56. Spain antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 57. Spain antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 58. Spain antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 59. Spain antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 60. Spain antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61. Norway antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 62. Norway antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 63. Norway antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 64. Norway antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 65. Norway antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 66. Denmark antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 67. Denmark antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 68. Denmark antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 69. Denmark antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 70. Denmark antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71. Sweden antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 72. Sweden antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 73. Sweden antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 74. Sweden antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 75. Sweden antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 76. Asia Pacific antibiotic resistance market, by country, 2021 - 2033 (USD Million)
  • Table 77. Asia Pacific antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 78. Asia Pacific antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 79. Asia Pacific antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 80. Asia Pacific antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 81. Asia Pacific antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 82. Japan antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 83. Japan antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 84. Japan antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 85. Japan antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 86. Japan antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87. China antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 88. China antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 89. China antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 90. China antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 91. China antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 92. India antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 93. India antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 94. India antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 95. India antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 96. India antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 97. Australia antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 98. Australia antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 99. Australia antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 100. Australia antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 101. Australia antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 102. South Korea antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 103. South Korea antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 104. South Korea antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 105. South Korea antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 106. South Korea antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 107. Thailand antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 108. Thailand antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 109. Thailand antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 110. Thailand antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 111. Thailand antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 112. Latin America antibiotic resistance market, by country, 2021 - 2033 (USD Million)
  • Table 113. Latin America antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 114. Latin America antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 115. Latin America antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 116. Latin America antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 117. Latin America antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 118. Brazil antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 119. Brazil antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 120. Brazil antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 121. Brazil antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 122. Brazil antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 123. Argentina antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 124. Argentina antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 125. Argentina antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 126. Argentina antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 127. Argentina antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 128. Middle East & Africa antibiotic resistance market, by country, 2021 - 2033 (USD Million)
  • Table 129. Middle East & Africa antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 130. Middle East & Africa antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 131. Middle East & Africa antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 132. Middle East & Africa antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 133. Middle East & Africa antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 134. South Africa antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 135. South Africa antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 136. South Africa antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 137. South Africa antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 138. South Africa antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 139. Saudi Arabia antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 140. Saudi Arabia antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 141. Saudi Arabia antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 142. Saudi Arabia antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 143. Saudi Arabia antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 144. UAE antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 145. UAE antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 146. UAE antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 147. UAE antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 148. UAE antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 149. Kuwait antibiotic resistance market, by disease, 2021 - 2033 (USD Million)
  • Table 150. Kuwait antibiotic resistance market, by pathogen, 2021 - 2033 (USD Million)
  • Table 151. Kuwait antibiotic resistance market, by drug class, 2021 - 2033 (USD Million)
  • Table 152. Kuwait antibiotic resistance market, by mechanism of action, 2021 - 2033 (USD Million)
  • Table 153. Kuwait antibiotic resistance market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Antibiotic resistance market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Antibiotic resistance market dynamics
  • Fig. 11 Antibiotic resistance market: Porter's five forces analysis
  • Fig. 12 Antibiotic resistance market: PESTLE analysis
  • Fig. 13 Disease market, 2021 - 2033 (USD Million)
  • Fig. 14 cUTI (complicated urinary tract infections) market, 2021 - 2033 (USD Million)
  • Fig. 15 CDI (Clostridioides difficile Infection) market, 2021 - 2033 (USD Million)
  • Fig. 16 ABSSSI (Acute Bacterial Skin and Skin Structure Infections) market, 2021 - 2033 (USD Million)
  • Fig. 17 HABP (hospital-acquired bacterial pneumonia) market, 2021 - 2033 (USD Million)
  • Fig. 18 CABP (community-acquired pneumonia) market, 2021 - 2033 (USD Million)
  • Fig. 19 cIAI (complicated intra-abdominal infection) market, 2021 - 2033 (USD Million)
  • Fig. 20 BSI (bloodstream infection) market, 2021 - 2033 (USD Million)
  • Fig. 21 Pathogens market, 2021 - 2033 (USD Million)
  • Fig. 22 E. coli market, 2021 - 2033 (USD Million)
  • Fig. 23 K. pneumoniae market, 2021 - 2033 (USD Million)
  • Fig. 24 P. aeruginosa market, 2021 - 2033 (USD Million)
  • Fig. 25 S. aureus market, 2021 - 2033 (USD Million)
  • Fig. 26 A. baumannii market, 2021 - 2033 (USD Million)
  • Fig. 27 S. pneumoniae market, 2021 - 2033 (USD Million)
  • Fig. 28 H. influenzae market, 2021 - 2033 (USD Million)
  • Fig. 29 CDI market, 2021 - 2033 (USD Million)
  • Fig. 30 E. faecium market, 2021 - 2033 (USD Million)
  • Fig. 31 Drug class market, 2021 - 2033 (USD Million)
  • Fig. 32 Oxazolidinones market, 2021 - 2033 (USD Million)
  • Fig. 33 Lipoglycopeptides market, 2021 - 2033 (USD Million)
  • Fig. 34 Tetracyclines market, 2021 - 2033 (USD Million)
  • Fig. 35 Combination therapies market, 2021 - 2033 (USD Million)
  • Fig. 36 Cephalosporins market, 2021 - 2033 (USD Million)
  • Fig. 37 Others market, 2021 - 2033 (USD Million)
  • Fig. 38 Mechanism of action market, 2021 - 2033 (USD Million)
  • Fig. 39 Protein synthesis inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 40 Cell wall synthesis inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 41 RNA synthesis inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 42 DNA synthesis inhibitors market, 2021 - 2033 (USD Million)
  • Fig. 43 Others market, 2021 - 2033 (USD Million)
  • Fig. 44 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 45 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 46 Retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 47 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 48 Antibiotic resistance market revenue, by region
  • Fig. 49 Regional marketplace: Key takeaways
  • Fig. 50 North America Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 51 U.S. country dynamics
  • Fig. 52 U.S. Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 53 Canada country dynamics
  • Fig. 54 Canada Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 55 Mexico country dynamics
  • Fig. 56 Mexico Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 57 Europe Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 58 UK country dynamics
  • Fig. 59 UK Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 60 Germany country dynamics
  • Fig. 61 Germany Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 62 France country dynamics
  • Fig. 63 France Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 64 Italy country dynamics
  • Fig. 65 Italy Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 66 Spain country dynamics
  • Fig. 67 Spain Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 68 Norway country dynamics
  • Fig. 69 Norway Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 70 Sweden country dynamics
  • Fig. 71 Sweden Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 72 Denmark country dynamics
  • Fig. 73 Denmark Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 74 Asia Pacific Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 75 Japan country dynamics
  • Fig. 76 Japan Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 77 China country dynamics
  • Fig. 78 China Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 79 India country dynamics
  • Fig. 80 India Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 81 Australia country dynamics
  • Fig. 82 Australia Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 83 South Korea country dynamics
  • Fig. 84 South Korea Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 85 Thailand country dynamics
  • Fig. 86 Thailand Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 87 Latin America Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 88 Brazil country dynamics
  • Fig. 89 Brazil Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 90 Argentina country dynamics
  • Fig. 91 Argentina Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 92 MEA Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 93 South Africa country dynamics
  • Fig. 94 South Africa Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 95 Saudi Arabia country dynamics
  • Fig. 96 Saudi Arabia Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 97 UAE country dynamics
  • Fig. 98 UAE Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 99 Kuwait country dynamics
  • Fig. 100 Kuwait Antibiotic resistance market, 2021 - 2033 (USD Million)
  • Fig. 101 Company categorization
  • Fig. 102 Company market position analysis
  • Fig. 103 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!